PDS Biotechnology
PDSB
47 hedge funds and large institutions have $6.64M invested in PDS Biotechnology in 2025 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 14 reducing their positions, and 15 closing their positions.
4.35% less ownership
Funds ownership: 16.3% → 11.95% (-4.3%)
15% less funds holding
Funds holding: 55 → 47 (-8)
33% less capital invested
Capital invested by funds: $9.9M → $6.64M (-$3.26M)
36% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 14
47% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IWA
Inspirion Wealth Advisors
Libertyville,
Illinois
|
+$313K |
| 2 |
Squarepoint
New York
|
+$228K |
| 3 |
Renaissance Technologies
New York
|
+$200K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$162K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$95.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$2.97M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$403K |
| 3 |
Millennium Management
New York
|
-$108K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$91K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$58.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
51
Virtu Financial
New York
| – | -$43K | -32,002 | Closed |
|
52
T. Rowe Price Associates
Baltimore,
Maryland
| – | -$33K | -24,263 | Closed |
|
|
MG
53
Marex Group
London,
| – | -$18.6K | -14,000 | Closed |
|
|
VPIM
54
Vanguard Personalized Indexing Management
Oakland,
California
| – | -$18.6K | -13,979 | Closed |
|
|
SFP
55
Sandbox Financial Partners
Bethesda,
Maryland
| – | -$16.8K | -12,666 | Closed |
|
|
CSS
56
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$14.4K | -10,861 | Closed |
|
|
BTI
57
Blue Trust Inc
Alpharetta,
Georgia
| – | -$5.99K | -4,500 | Closed |
|
|
TRCT
58
Tower Research Capital (TRC)
New York
| – | -$2.66K | -2,002 | Closed |
|
|
RA
59
Rise Advisors
Rochester,
New York
| – | -$1.12K | -840 | Closed |
|
|
PD
60
Point72 (DIFC)
Dubai,
United Arab Emirates
| – | -$66 | -50 | Closed |
|
|
CIAM
61
Caitong International Asset Management
Hong Kong
| – | -$1 | -1 | Closed |
|
62
National Bank of Canada
Montreal,
Quebec, Canada
| – | -$1 | -1 | Closed |
|
PDSB Hedge Fund Activity: Q3 2025 in Review
47 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q3 2025, worth a combined $6.64M — down 33% from $9.9M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of PDSB and 8 opened new positions — a net loss of 7 holders — while 14 trimmed existing stakes and 9 added.
The largest buyer was Inspirion Wealth Advisors, adding an estimated $313K. The largest seller was Armistice Capital, exiting entirely with an estimated $2.97M sold.
- 47 institutional investors held PDS Biotechnology (PDSB) as of Q3 2025, down from 55 in Q2 2025.
- Funds reported $6.64M of PDS Biotechnology stock for Q3 2025, down 33% quarter-over-quarter.
- 8 funds opened new PDS Biotechnology positions in Q3 2025 and 15 closed out, a net change of -7 holders.
- The largest PDS Biotechnology buyer in Q3 2025 was Inspirion Wealth Advisors, an estimated $313K added.
- The largest PDS Biotechnology seller in Q3 2025 was Armistice Capital, an estimated $2.97M sold.
Based on aggregated 13F filings for Q3 2025.